NCT00274326已完成3 期
A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial Evaluating the Effect of a Vasopressin V2 Receptor Antagonist (SR121463B) on Serum Sodium in Patients With Dilutional Hyponatremia
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Sanofi
- 入组人数
- 150
- 试验地点
- 15
- 主要终点
- PHARMACOKINETICS:Plasma SR121463B concentrations
研究概览
简要总结
Primary:
- To assess the efficacy of SR121463B in correcting hyponatremia in patients with dilutional hyponatremia other than SIADH or cirrhosis
Secondary:
- To assess the long-term efficacy of SR121463B in maintaining normonatremia in these patients
- To assess the safety and tolerability of SR121463B
详细描述
SR121463B is an orally effective non-peptide, potent, and highly selective V2 receptor antagonist causing free water elimination in animals and humans
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or Female patients aged 18 higher
- •Dilutional Hyponatremia with serum sodium between 115 and 132 mmol/L
- •Ability to give written informed consent (the informed consent may be signed by a legally authorized representative if the patient is unable to sign)
排除标准
- •Presence of known or untreated adrenal insufficiency, SIADH or cirrhosis, or hyperthyroidism
- •Presence of signs of hypovolemia
- •Administration of other V2 receptor antagonists or demeclocycline or lithium within one month and urea within two days prior to study drug administration
- •Presence of uncontrolled diabetes with fasting glycemia ³ 200 mg/dL (³ 11.09 mmol/L)
- •Patients considered by the Investigator unsuitable candidates to receive an investigational drug (e.g., presence of any neurological symptoms that may worsen in five days, based on the judgment of the Investigator, or presence of any neurological symptoms for which the persistence of hyponatremia over several days may be deleterious)
- •Administration of inducers of CYP3A4 (phenobarbital, phenytoin, rifampin, Saint John's Wort) or potent and moderate inhibitors of CYP3A4 within two weeks prior to study drug administration
- •Presence or history of allergic reaction to SR121463B8
- •Previous study with SR121463B
- •Inadequate hematological, renal, and hepatic functions: hemoglobin (Hb) < 9 g/dL, neutrophils < 1,500/mm3, platelets < 100,000/mm3, serum creatinine > 175 mol/L (or clearance of creatinine < 30 mL/min for sites where Ethics Committees require this parameter), serum alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) > 2 x upper limit of normal (ULN)
- •QTCB 500 ³ ms
- •Positive pregnancy test and absence of medically approved contraceptive methods (e.g., surgical sterilization of more than one month duration, oral contraception or intrauterine device in combination with either diaphragm, condom, or spermicide) for females of childbearing potential
- •Pregnancy or breast-feeding
结局指标
主要结局
PHARMACOKINETICS:Plasma SR121463B concentrations
EFFICACY:Serum Sodium
SAFETY:Physical examination, vital signs, adverse events, electrocardiogram, hematology, serum chemistry
次要结局
- Weight; EQ-5D and pharmaco-economic assessments
研究者
研究点 (15)
Loading locations...
相似试验
已完成
3 期
Efficacy and Safety of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone SecretionInappropriate ADH SyndromeHyponatremiaNCT00264927Sanofi77
Unknown
2 期
Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute HyponatremiaNon-hypovolemic Non-acute HyponatremiaNCT01507727Jiangsu HengRui Medicine Co., Ltd.240
进行中（未招募）
不适用
THE BALANCE study: Treatment of Hyponatremia based on Lixivaptan in NYHA class III/IV Cardiac Patient Evaluation - CK-LX3401Hyponatremia in NYHA Class III/IV Cardiac PatientMedDRA version: 9.1Level: LLTClassification code 10021036Term: HyponatraemiaEUCTR2006-002567-62-ITCARDIOKINE BIOPHARMA, LLC650
已完成
2 期
Mineralocorticoid Receptor Antagonists (MRA) in Heart Failure (HF) and Loop Diuretic ResistanceHeart FailureNCT02585843Columbia University20
进行中（未招募）
1 期
THE BALANCE Study: Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient EvaluatioHyponatremiaEUCTR2006-002567-62-SKCardiokine Biopharma, LLC650